- N Engl J Med 2022; 387:842-843
The development of a highly effective, oral, 6-month regimen for the treatment of multidrug-resistant tuberculosis, which previously took 18 to 24 months to cure, is one of the defining achievements of the tuberculosis research community in this century. The results of the Nix-TB study, which were published in the
- N Engl J Med 2022; 387:850-852
Investigators report findings from the use of an all-oral regimen of bedaquiline, pretomanid, and linezolid in patients in the United States with multidrug-resistant or extensively drug-resistant tuberculosis.
- N Engl J Med 2022; 387:810-823
A randomized trial of bedaquiline–pretomanid–linezolid for highly drug-resistant tuberculosis assessed the use of linezolid at 600 or 1200 mg for 9 or 26 weeks; the 600-mg dose for 26 weeks had a favorable profile.
- N Engl J Med 2022; 387:799-809
In this study involving 1257 pregnancies among persons treated for HIV-1 infection during pregnancy, dolutegravir was better at suppressing viral loads than other regimens, without evident safety concerns.
- Original ArticleAug 28, 202210.1056/NEJMoa2209051
Among patients with rheumatic heart disease and atrial fibrillation who received a vitamin K antagonist or rivaroxaban, the rate of stroke, systemic embolism, MI, or death from vascular or unknown causes was lower with a VKA, without increased bleeding.
- N Engl J Med 2022; 387:749-750
In this issue of the Journal, Thornhill et al. report on 528 persons with monkeypox in a cohort spanning 16 countries on five continents.1 The authors provide important demographic, epidemiologic, and clinical details on the largest reported cohort of patients in the latest emerging infectious disease...
- N Engl J Med 2022; 387:679-691
In this report, 528 cases of monkeypox across 16 countries are described. Rash, mucosal lesions, fever, lethargy, and lymphadenopathy were common clinical findings. Few patients were hospitalized.
- N Engl J Med 2022; 387:661-662
A patient in whom Japanese encephalitis was diagnosed in February 2021 has been identified as a likely sentinel human case of the 2022 outbreak of the disease in Australia.
- N Engl J Med 2022; 387:579-581
Tecovirimat might speed resolution of monkeypox illness and improve outcomes, but how can we manage compassionate access to a drug whose safety and efficacy in humans have not been established?
- N Engl J Med 2022; 387:599-610
In this trial involving overweight or obese outpatients with Covid-19, investigators found that none of three repurposed drugs (metformin, ivermectin, and fluvoxamine) reduced the risk of serious disease.
- N Engl J Med 2022; 387:654-655
In practicing evidence-based medicine, physicians use the best evidence currently available on safety and efficacy in making decisions on treatment choices for their patients. During the Covid-19 pandemic, some of the early treatment trials were rushed, leading to studies that were badly conducted1 or had too few patients.
- N Engl J Med 2022; 387:568-570
In this ongoing household cohort study in Nicaragua, previous SARS-CoV-2 infection during a second Covid-19 wave provided some protection against symptomatic Covid-19, with greater protection against severe illness.
- N Engl J Med 2022; 387:451-451
A 68-year-old woman living in Japan presented with a 5-day history of rash and fevers. She had been bitten by a tick 1 week earlier. Examination revealed a petechial rash and eschar on the ankle.
- N Engl J Med 2022; 387:460-461
In 2020, a total of 241 million cases of malaria and 627,000 malaria-related deaths were reported.1 In this issue of the Journal, Wu and colleagues2 present a new approach to provide immune protection with a next-generation monoclonal antibody against Plasmodium falciparum malaria...
- N Engl J Med 2022; 387:397-407
This phase 1 trial examined an engineered monoclonal antibody, L9LS, targeting the sporozoite. L9LS protected against malaria infection in a human challenge model.
- N Engl J Med 2022; 387:462-465
Monoclonal antibodies are commonly used in the treatment of diseases, including cancer. A next-generation antibody for the prevention of malaria exploits different vulnerabilities of Plasmodium falciparum, the major cause of malaria.
- N Engl J Med 2022; 387:470-472
In this report, investigators in China identified a new henipavirus associated with a febrile human illness. This virus was also found in shrews.
- N Engl J Med 2022; 387:102-105
Appropriately, Russia’s war of aggression in Ukraine has prompted a massive humanitarian response — but the assault has intensified and time is running out.
- N Engl J Med 2022; 387:e3
Implementing best practices could compress vaccine-development timelines in the event of a new pandemic. Further speeding of development will require substantial shifts from the current development paradigm, supported by scientific advances.